Access the full text.
Sign up today, get DeepDyve free for 14 days.
V R 1 is the calculated asymptotic variance of Z under alternative hypothesis R = R 1
Kenneth Mayer, J. Molina, Melanie Thompson, Peter Anderson, K. Mounzer, Joss Wet, E. Dejesus, H. Jessen, Robert Grant, Peter Ruane, Pamela Wong, R. Ebrahimi, Lijie Zhong, A. Mathias, C. Callebaut, Sean Collins, M. Das, S. McCallister, Diana Brainard, C. Brinson, A. Clarke, P. Coll, Frank Post, C. Hare (2020)
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialLancet (London, England), 396
M. Thigpen, P. Kebaabetswe, L. Paxton, Dawn Smith, C. Rose, Tebogo Segolodi, Faith Henderson, S. Pathak, F. Soud, K. Chillag, Rodreck Mutanhaurwa, Lovemore Chirwa, M. Kasonde, Daniel Abebe, Evans Buliva, R. Gvetadze, Sandra Johnson, T. Sukalac, Vasavi Thomas, C. Hart, Jeffrey Johnson, C. Malotte, C. Hendrix, J. Brooks (2012)
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.The New England journal of medicine, 367 5
R. Mera, S. Scheer, Christoph Carter, M. Das, Julius Asubonteng, S. McCallister, J. Baeten (2019)
Estimation of new HIV diagnosis rates among high‐risk, PrEP‐eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United StatesJournal of the International AIDS Society, 22
B. Hanscom, James Hughes, B. Williamson, D. Donnell (2018)
Adaptive non-inferiority margins under observable non-constancyStatistical Methods in Medical Research, 28
S. Facente, E. Grebe, C. Pilcher, M. Busch, G. Murphy, A. Welte (2020)
Estimated dates of detectable infection (EDDIs) as an improvement upon Fiebig staging for HIV infection datingEpidemiology and Infection, 148
Catherine Koss, E. Charlebois, J. Ayieko, D. Kwarisiima, J. Kabami, L. Balzer, Mucunguzi Atukunda, F. Mwangwa, James Peng, Yusuf Mwinike, A. Owaraganise, G. Chamie, V. Jain, N. Sang, Winter Olilo, L. Brown, C. Marquez, Kevin Zhang, T. Ruel, C. Camlin, J. Rooney, D. Black, T. Clark, M. Gandhi, C. Cohen, E. Bukusi, M. Petersen, M. Kamya, D. Havlir (2020)
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH studyThe Lancet. HIV, 7
(2019)
Impact of HIV-1 subtype and sex on Sedia limiting antigen avidity assay performance
R. Kassanjee, Thomas McWalter, T. Bärnighausen, A. Welte (2012)
A New General Biomarker-based Incidence EstimatorEpidemiology, 23
K. Mayer, A. Agwu, D. Malebranche (2020)
Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative ReviewAdvances in Therapy, 37
C. Mullick, J. Murray (2020)
Correlations between HIV infection and rectal gonorrhea incidence in men who have sex with men: Implications for future HIV pre-exposure prophylaxis trials.The Journal of infectious diseases
J. Baeten, D. Donnell, P. Ndase, N. Mugo, J. Campbell, Jonathan Wangisi, J. Tappero, E. Bukusi, C. Cohen, E. Katabira, A. Ronald, Elioda Tumwesigye, E. Were, K. Fife, J. Kiarie, C. Farquhar, G. John-Stewart, Aloysious Kakia, J. Odoyo, A. Mucunguzi, E. Nakku-Joloba, R. Twesigye, K. Ngure, Cosmas Apaka, H. Tamooh, Fridah Gabona, A. Mujugira, D. Panteleeff, Katherine Thomas, L. Kidoguchi, M. Krows, Jennifer Revall, Susan Morrison, Harald Haugen, Mira Emmanuel-ogier, Lisa Ondrejcek, R. Coombs, L. Frenkel, C. Hendrix, Namandjé Bumpus, D. Bangsberg, J. Haberer, W. Stevens, J. Lingappa, C. Celum (2012)
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.The New England journal of medicine, 367 5
P. Sullivan, A. Siegler (2018)
Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and emerging models of PrEP implementation.Sexual health, 15 6
D. Glidden (2019)
Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis.Current Opinion in HIV and AIDS
R. Grant, J. Lama, P. Anderson, V. McMahan, A. Liu, Lorena Vargas, P. Goicochea, M. Casapia, J. Guanira-Carranza, María Ramírez-Cardich, Orlando Montoya-Herrera, T. Fernández, V. Veloso, S. Buchbinder, S. Chariyalertsak, M. Schechter, L. Bekker, K. Mayer, E. Kallás, K. Amico, K. Mulligan, Lane Bushman, Robert Hance, Carmela Ganoza, P. Defechereux, Brian Postle, Furong Wang, J. McConnell, Jia-Hua Zheng, Jean Lee, J. Rooney, H. Jaffe, Ana Martínez, D. Burns, D. Glidden (2010)
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.The New England journal of medicine, 363 27
E. Kaplan, R. Brookmeyer (1999)
Snapshot Estimators of Recent HIV Incidence RatesOper. Res., 47
AbstractObjectivesThe past decade has seen tremendous progress in the development of biomedical agents that are effective as pre-exposure prophylaxis (PrEP) for HIV prevention. To expand the choice of products and delivery methods, new medications and delivery methods are under development. Future trials of non-inferiority, given the high efficacy of ARV-based PrEP products as they become current or future standard of care, would require a large number of participants and long follow-up time that may not be feasible. This motivates the construction of a counterfactual estimate that approximates incidence for a randomized concurrent control group receiving no PrEP.MethodsWe propose an approach that is to enroll a cohort of prospective PrEP users and aug-ment screening for HIV with laboratory markers of duration of HIV infection to indicate recent infections. We discuss the assumptions under which these data would yield an estimate of the counterfactual HIV incidence and develop sample size and power calculations for comparisons to incidence observed on an investigational PrEP agent.ResultsWe consider two hypothetical trials for men who have sex with men (MSM) and transgender women (TGW) from different regions and young women in sub-Saharan Africa. The calculated sample sizes are reasonable and yield desirable power in simulation studies.ConclusionsFuture one-arm trials with counterfactual placebo incidence based on a recency assay can be conducted with reasonable total screening sample sizes and adequate power to determine treatment efficacy.
Statistical Communications in Infectious Diseases – de Gruyter
Published: Jan 1, 2021
Keywords: counterfactual placebo incidence; HIV prevention; pre-exposure prophylaxis; recency assay; sample size calculation
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.